Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy-Reference-Cited by-同舟云学术

Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

Published:2008-10-22 Issue:2 Volume:116 Page:359-369
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Colleoni Marco,Bagnardi Vincenzo,Rotmensz Nicole,Gelber Richard D.,Viale Giuseppe,Pruneri Giancarlo,Veronesi Paolo,Torrisi Rosalba,Cardillo Anna,Montagna Emilia,Campagnoli Elisabetta,Luini Alberto,Intra Mattia,Galimberti Viviana,Scarano Eloise,Peruzzotti Giulia,Goldhirsch Aron

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-008-0223-y.pdf

Reference38 articles.

1. MacGrogan G, Mauriac L, Durand M et al (1996) Primary chemo-therapy in breast invasive carcinoma: predictive value of the immuno-histochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74:1458–1465

2. Fisher ER, Wang J, Bryant J et al (2002) Pathobiology of preoperative chemotherapy findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18. Cancer 95:681–695. doi: 10.1002/cncr.10741

3. Faneyte IF, Schrama JG, Peterse JL et al (2003) Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88:406–412. doi: 10.1038/sj.bjc.6600749

4. Bear HD, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165–4174. doi: 10.1200/JCO.2003.12.005

5. Ring AE, Smith IE, Ashley S (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91:1–6. doi: 10.1038/sj.bjc.6602235

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran;Archives of Iranian Medicine;2024-04-01

2. MRI Combining with Clinicopathological Factors Predict the Negative Rate of Axillary Lymph Nodes in Breast Cancer after Neoadjuvant Chemotherapy;Advances in Clinical Medicine;2023

3. ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer;Frontiers in Oncology;2022-10-20

4. Characterization of 940 Chinese patients with triple-positive breast cancer by clinicopathological and treatment outcomes;2022-10-11

5. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival;ESMO Open;2021-08